Le Lézard
Classified in: Health, Science and technology
Subject: LICENSING AGREEMENTS

VitalHub Signs Multi-Year Expansion Licensing Contract with Hampshire Hospitals NHS Foundation Trust


TORONTO, June 23, 2021 (GLOBE NEWSWIRE) -- VitalHub Corp. (the "Company" or "VitalHub") (TSXV: VHI) is pleased to announce the closing of a multi-year licensing transaction of recently acquired subsidiary Intouch with Health's ("Intouch") Synopsis platform with Hampshire Hospitals NHS Foundation Trust (the "Trust" or "Hampshire Hospitals").

The deal constitutes a 3-year licensing contract for the Company's proprietary, award-winning Synopsis platform. Hampshire Hospitals comprise the Royal Hampshire County Hospital (Winchester), Basingstoke and North Hampshire Hospital (Basingstoke), and Andover War Memorial Hospital (Andover). Establishing a partnership with the Trust will extend VitalHub's growing reach into the Hampshire and West Berkshire regions, serving a population of approximately 600,000 people. This contract will result in over 50,000 Synopsis iQ pre-operative assessments being executed across Trust sites.

The deal marks an expansion of VitalHub services across the Trust's hospital sites, with Hampshire Hospitals previously using Intouch's Flow Manager system, a clinician dashboard that tracks patient progress and activity, at the Basingstoke and North Hampshire Hospital.

This partnership originated from Hampshire Hospitals need for better surgical backlog and landscape organization. Synopsis is a completely digital pre-operational assessment platform that provides clarity, efficiency and value to health systems. By removing paper trails and increasing data security through complete digitalization, Synopsis delivers significant organizational benefits to healthcare organizations. Consequently, the Synopsis platform served as an ideal solution to address the Trust's pre-operative needs.

"This deal reinforces the consistent and ongoing increase in Synopsis platform's market exposure, and continues to deepen our penetration of the UK market," said Dan Matlow, CEO of VitalHub Corp. "This market need for better organization in pre-operative processes is not unique to Hampshire Hospitals. The medical community collectively recognizes a need for systems to support health systems with electronic records to improve efficiency, economy and patient safety. We look forward to continuing to expand our reach, both within the UK market, and on a global basis."

ABOUT HAMPSHIRE HOSPITALS NHS FOUNDATION TRUST

Hampshire Hospitals NHS Foundation Trust, established in 2012, pride themselves on their commitment to providing patients, visitors and staff with a high quality and safe environment. The Trust has three hospital sites across Hampshire and parts of west Berkshire. The Trust employs nearly 6,000 staff and treat approximately 600,000 patients annually.

ABOUT VITALHUB

Software for Health and Human Services providers designed to simplify the user experience & optimize outcomes.

VitalHub provides technology to Health and Human Services providers including; Hospitals, Regional Health Authorities, Mental Health, Long Term Care, Home Health, Community and Social Services. VitalHub solutions span the categories of Electronic Health Record (EHR), Case Management, Care Coordination, Patient Flow & Operational Visibility, and DOCit Mobile Apps.

The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive M&A plan. Currently, VitalHub serves 275+ clients across Canada, USA, UK, Australia, Qatar, and Latvia. VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The Company is publicly traded on the TSX Venture Exchange under the symbol "VHI".

CONTACT INFORMATION

Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
[email protected]

CAUTIONARY STATEMENT

This press release includes forward-looking statements regarding the Corporation and its business, which may include, but is not limited to, statements with respect to the appointment of a new directors. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the technology industry, failure to obtain regulatory or shareholder approvals, market conditions, economic factors, the equity markets generally and risks associated with growth and competition. Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Corporation undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. 



These press releases may also interest you

at 03:00
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...



News published on and distributed by: